Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation